BioSpace News Archive

The global contact cast system market is expected to exhibit a steady growth owing to rise in diabetic cases across the globe.

Antidepressants are drugs used for the treatment of depressive disorders including dysthymia, obsessive compulsive disorder, anxiety, chronic pain, eating disorders, and neuropathic pain.

Rancho Santa Fe Bio, Inc., a San Diego, California-based clinical-stage cardiovascular platform company, announced that it has entered into an exclusive worldwide license agreement with Sanofi, a global biopharmaceutical company.

Xilio Therapeutics, a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug application to evaluate its checkpoint inhibitor product candidate, XTX101, as a potential treatment for patients with solid tumors.

Foresight Diagnostics, the emerging leader in blood-based lymphoma disease monitoring, announced that clinical performance of its minimal residual disease detection platform in diffuse large B-cell lymphoma will be presented at the 16th International Conference on Malignant Lymphoma on June 18-22, 2021.

Eagle Pharmaceuticals, Inc. announced that it has responded to the Complete Response Letter for its Abbreviated New Drug Application for vasopressin received from the U.S. Food and Drug Administration in February 2021.

Algernon Pharmaceuticals Inc. is pleased to announce that all of the required permits and licenses for the manufacture of its cGMP supply of AP-188 have been received and as a result, is targeting its Phase 1 human study to be conducted at Hammersmith Medicines Research UK in Q4, 2021.

The U.S. Food and Drug Administration Center for Biologics Evaluation and Research has granted approval to Sanofi Pasteur, the vaccines global business unit of Sanofi, for an additional influenza manufacturing facility located in Swiftwater, PA.

OncoNano Medicine, Inc. announced the raise of an approximate $50 million Series B financing led by the healthcare investment team at Advantech Capital, a China-based cross border institutional investment fund.

Pinteon Therapeutics, a biotechnology company focused on protecting neuronal health by targeting neurotoxic forms of tau, announced it has received a $3 million award from Advanced Technology International to support the company’s Phase 1 study of PNT001 in hospitalized patients with acute traumatic brain injury.